xml version="1.0" encoding="utf-8"?              

   0000203527 false        0000203527   2020-02-18 2020-02-19    iso4217:USD   xbrli:shares     iso4217:USD   xbrli:shares       

SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, D.C. 20549 

___________ 

FORM 8-K 

CURRENT REPORT 

PURSUANT TO SECTION 13 OR 15(d) OF THE 

SECURITIES EXCHANGE ACT OF 1934 

 Date of report (Date of earliest event reported) February 19, 2020  

 VARIAN MEDICAL SYSTEMS, INC. 

 (Exact Name of Registrant as Specified in its Charter)  

  [DATA_TABLE_REMOVED] 

  [DATA_TABLE_REMOVED] 

 Registrant's telephone number, including area code (650) 493-4000  

 Not Applicable 

 (Former Name or Former Address, if Changed Since Last Report)  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  

Securities registered pursuant to Section 12(b) of the Act: 

  [DATA_TABLE_REMOVED] 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b - 2 of the Securities Exchange Act of 1934. 

Emerging growth company ¨ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 

On February 19, 2020, Gary E. Bischoping, Jr., President, Interventional Oncology Solutions of Varian Medical Systems, Inc. (the “Company”), informed the Company that he will be resigning from the Company effective March 6, 2020. 

2  

SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

  [DATA_TABLE_REMOVED] 

Dated: February 21, 2020 

3